drugset
drugset / Trial / NCT02256709

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

NCT02256709 ↗

Phase 1 Completed 70 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability and pharmacokinetics (including comparisons of different formulations and investigation of food effect)

Timeline

Start
2004-04
Primary completion
2004-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBP 5371 CL Unknown 10 mg Oral
Subject BIBP 5371 CL Unknown 50 mg Oral
Subject BIBP 5371 CL Unknown 100 mg Oral
Subject BIBP 5371 CL Unknown 350 mg Oral

Indications

No indication recorded.